in May 2025, an 85-year old patient with chronic renal failure was diagnosed via a routine ultrasound, a 3.3 cm tumor in the right kidney. Due to multiple comorbidities patient was an unlikely surgical candidate, and the urology tumor board decided on cryoablation. In October 2025, a cryoablation and biopsy using CAS-One IR was performed and at this time the tumor was then 4.3 cm. Three IceForce probes were placed in the tumor and a hydro-dissection was performed to push away the colon. AblaSure showed a complete treatment and the patient was released the next day.
Planning scan showing accurate tumor segmentation and the planning of three IceForce probes and one hydrodissection needle.
3D reconstruction of the planning
Verify scan showing the position of the three IceForce with 1.5cm separation and full coverage of the tumor. The colon has been pushed away by the hydrodissection.
AblaSure showing full coverage after the 2nd freezing cycle.
AblaSure confirming full coverage of the tumor post retrieval of the needles
Name: Prof. Dr. Christian Neumann
Institution: Barmherzige Bruder - Vienna, Austria
Patient age and sex: Male, 85 years-old
Initial condition:
- Patient followed for chronic renal failure
- Diagnosed in May 2025 during a routine ultrasound with a 3.3 cm tumor in the right kidney confirmed by CT
- Multiple comorbidities including Type 2 diabetes, hypertension and coronary and carotid disease
- Given the high risk, MDT decided in June 2025 on a cryoablation and simultaneous biopsy to limit the number of procedures
Treatment:
- Patient was in prone position under general anesthesia
- Synchronous core biopsy taken immediately before ablation (histology revealed Oncocytoma)
- 3 IceForce probes from Boston Scientific were planned and deemed significant enough to cover the lesion and margin
- Hydrodissection was planned and executed with CAS-One IR to create space between the colon and Kidney
- Needles were all placed in one insertion push with less than 1mm lateral deviation
- The procedure took 75 minutes
Result:
- AblaSure® showed a complete coverage after the 2nd freeze cycle and also confirmed post thawing and retrieval of the needles.
- The patient was discharged the following day with no complications except some hematuria a week later with no blood count change. (probable UTI)
Conclusion:
- The planning, navigation, and ablation confirmation with CAS-One® IR made this complex cryoablation easy and quick - even with necessary hydrodissection and high comorbidities.
- Prof. Dr. Christian Neumann said about this case " CAS-One IR was extremely helpful in planning the complete coverage of this T1b-tumor with 3 needles - and the improved segmentation of the ablated area via AblaSure made us confident that we had a sufficient treatment"
Learn more about the stereotactic navigation system
CAS-One IR.